Alendronate sodium

• CAT Number: A000595
• CAS Number: 121268-17-5
• Molecular Formula: C₄H₁₂NaNO₇P₂ · 3 H₂O
• Molecular Weight: 325.12
• Purity: 98%
• Synonyms: G-704650, MK-217; 121268-17-5; Alendronate monosodium trihydrate; Alendronate sodium hydrate; ALENDRONATE SODIUM; Alendronate sodium trihydrate
• Target: Farnesyl Diphosphate Synthase
• Solubility: Limited solubility
• Appearance: white solid powder
• Storage: -20°C
• IUPAC Name: sodium;(4-amino-1-hydroxy-1-phosphonobutyl)-hydroxyphosphinate;trihydrate
• InChI: InChI=1S/C4H13NO7P2.Na.3H2O/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;;;;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);;3*1H2/q;+1;;;/p-1
• InChIKey: DCSBSVSZJRSITC-UHFFFAOYSA-M
• SMILES: C(CC(O)(P(=O)(O)O)P(=O)(O)[O-])CN.O.O.O.[Na+]

Alendronate sodium（Cat No.:A000595）is a bisphosphonate medication used to treat and prevent osteoporosis in postmenopausal women and men. It works by inhibiting osteoclast-mediated bone resorption, leading to increased bone mineral density and reduced risk of fractures. Alendronate is also used to treat Paget’s disease of bone. Administered orally, it is typically taken once weekly to improve patient compliance. Common side effects include gastrointestinal discomfort, such as heartburn and esophageal irritation. Alendronate sodium is a vital therapy in managing osteoporosis, helping to maintain bone strength and prevent fractures.